<DOC>
	<DOCNO>NCT02667483</DOCNO>
	<brief_summary>This phase I/II study evaluate safety , tolerability , efficacy , pharmacokinetic ( PK ) profile DS-5141b patient Duchenne muscular dystrophy ( DMD ) determine dosage subsequent study .</brief_summary>
	<brief_title>Study DS-5141b Patients With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Confirmation outofframe deletion ( ) could correct dystrophin gene exon 45 skipping . Intact muscle adequate quality biopsy allow evaluation efficacy study drug . Boys age 5 year &lt; 11 year . Patients able walk least 325 meter 6minutes walk test . Glucocorticoidnaive patient , patient use glucocorticoid least 6 month prior enrollment study dose change least 3 month prior enrollment . A genetic mutation expect expression dystrophin protein dystrophin gene exon 45 skipping . A concurrent illness DMD cause muscle weakness and/or impairment motor function . Current history severe disorder . Left ventricular ejection fraction ( LEVF ) &lt; 55 % . Corrected QT interval ( QTc ) &gt; 0.45 sec .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>Oligonucleotides , Antisense</keyword>
</DOC>